I was looking at Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), and noticed it had a chart pattern like the Cannabis sector rising from. 13 cents per share and rallying more than 400% to the current .70 cent level. After looking what they did I realized they were in a totally different industry. Teaser – I despise cancer so this is something I care deeply about.
The company is a clinical stage biopharmaceutical company developing therapeutics for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment.
Rexahn Pharmaceuticals, Inc’s (NYSEMKT:RNN) product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies show that certain of Rexahn’s product candidates may be effective against multiple types of cancer, drug-resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has a broad oncology pipeline. A look at the chart below shows the nice move the stock has achieved in 2017.
The main driver in my opinion was when the company announced that is has begun enrolling patients into a Phase IIa clinical study of Supinoxin™ in metastatic triple negative breast cancer. The study will evaluate the safety and efficacy of Supinoxin™ in patients with metastatic TNBC who have failed prior treatments.
Find out when Rexahn Pharmaceuticals stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
“The dosing of the first patient in the Phase IIa clinical trial with Supinoxin™ is a major milestone for the program,” said Peter D. Suzdak, Ph.D., Chief Executive Officer of Rexahn. “Our decision to focus initially on triple negative breast cancer underscores our commitment to developing our targeted treatments for cancers that are difficult to treat and for which there are limited treatment options. There is currently no approved drug treatment for TNBC, and no established standard of care, so there is a tremendous unmet medical need.”
“Supinoxin™ has a unique mechanism of action,” said Ely Benaim, M.D., Chief Medical Officer. “It targets a key biological pathway implicated in cancer cell proliferation. We have seen very promising activity in our preclinical models of triple negative breast cancer so we look forward to the preliminary readout from this first clinical study, which we anticipate later this year.”
“This is the first Phase IIa study with Supinoxin™ and our initial proof of concept study in triple negative breast cancer,” continued Dr. Benaim. “We plan also to evaluate Supinoxin™ in combination with other cancer treatments in triple negative breast cancer and in other solid tumors.”
The Phase IIa clinical proof-of-concept study is an open-label evaluation of the safety and efficacy of Supinoxin™ monotherapy in patients with metastatic triple negative breast cancer who have failed multiple prior chemotherapeutic regimens. The study will recruit an initial 10 patients and can be extended up to 50 patients, if warranted, based on the data readout from the initial cohort of patients. The primary endpoint is progression free survival. Patients will be enrolled at seven study sites in the United States. Based on the initial clinical data, we may conduct additional clinical studies looking at the combination of Supinoxin together with other anti-cancer agents in TNBC.
Supinoxin™ (RX-5902) is an orally administered, potential first-in-class, small molecule modulator of the β-catenin pathway — a key biological pathway that is activated in tumor cells leading to production of multiple cancer oncogenes and tumor proliferation and metastasis. Supinoxin™ modulates the pathway through inhibition of the interaction of phosphorylated p68 (a regulatory protein) with β-catenin.
Supinoxin™ has been shown to significantly inhibit tumor growth in a preclinical xenograft model of triple negative breast cancer. In addition, it was shown to have markedly synergistic effects when used in combination with a range of commonly used cytotoxics including paclitaxel, cisplatin and doxorubicin against triple negative breast cancer cell lines in in vitro studies.
Supinoxin™ has been evaluated in a Phase I dose-escalation study in patients with a diverse range of metastatic, treatment-refractory tumors including breast, ovarian, colorectal and neuroendocrine tumors. Supinoxin™ was safe and well tolerated at the doses tested with no dose limiting toxicities or treatment-related serious adverse events. The most frequently reported drug related adverse events were mild nausea, vomiting and fatigue. The study showed preliminary evidence of clinical activity with seven patients experiencing disease stabilization and three patients continuing treatment beyond one year.
For Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) the triple negative breast cancer refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) or Her2/neu.
The most effective breast cancer treatments target those three receptors, which are lacking in TNBC, and therefore, the available targeted therapies such as Herceptin (trastuzumab) or hormonal therapies are usually ineffective in this sub-group of breast cancer patients. TNBC is also more aggressive than other types of breast cancer and is more likely to recur.
There are currently no FDA-approved treatments for TNBC and there is no standard chemotherapy treatment for patients. TNBC accounts for approximately 15-20% of all breast cancer cases with an annual incidence of 30,000 patients in the US and over 150,000 worldwide. It is clear the company is on a path to solution in 2017, and often the share price leads the way. For continuing coverage on shares of Rexahn Pharmaceuticals stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!